Citations 3
The BCL-2 Inhibitor Venetoclax Augments Immune Effector Function Mediated by Fas Ligand, TRAIL, and Perforin/Granzyme B, Resulting in Reduced Plasma Viremia and Decreased HIV Reservoir Size during Acute HIV Infection in a Humanized Mouse Model
Chandrasekar, Aswath P. , Cummins, Nathan W. , Natesampillai, Sekar, Misra, Anisha , Alto, Alecia , Laird, Greg M., Laird, Greg , Cummins, Nathan W , Badley, Andrew D.
Journal of Virology | November 30, 2022 | Volume: 96 | Issue: 24 | Pages: No page available
This study is the first to examine the applicability of BCL-2 inhibition in the setting of active HIV infectionin vivo. Furthermore, this study demonstrates that venetoclax significantly enhances target cell killing induced by Fas ligand, TRAIL, and perforin/granzyme B and synergistically enhances autologous NK and CD8 cells’ killing of target cells.
The Combination of Venetoclax and Ixazomib Selectively and Efficiently Kills HIV-Infected Cell Lines but Has Unacceptable Toxicity in Primary Cell Models
Alto, Alecia , Natesampillai, Sekar, Chandrasekar, Aswath P. , Krogman, Ashton , Shweta, Fnu , VanLith, Caitlin J. , Yao, Joseph D. , Cummins, Nathan W. , Badley, Andrew D. , Misra, Anisha , VanLith, Caitlin, Cummins, Nathan W , Badley, Andrew D , Shweta, Fnu
Journal of Virology | April 5, 2021 | Volume: 95 | Issue: 12 | Pages: No page available
A cure for HIV would require eliminating cells that contain the virus in a latent form from the body. Current antiretroviral medications are unable to rid the body of latently infected cells. Here, we show that a combination of investigational agents—ixazomib plus venetoclax—which reactivate latent virus and predispose infected cells to apoptosis may reduce latent virus in a T cell model, but at the expense of nonspecific toxicity in primary cells.
A simple automated approach to measure mouse whole gut transit
Kacmaz, Halil, Alto, Alecia , Knutson, Kaitlyn R. , Linden, David R. , Gibbons, Simon J. , Farrugia, Gianrico , Beyder, Arthur , Knutson, Kaitlyn, Linden, D R , Beyder, Arthur , Gibbons, S J
Neurogastroenterology & Motility | October 1, 2020 | Volume: 33 | Issue: 2 | Pages: No page available
AbstractBackgroundGastrointestinal (GI) motility is a complex physiological process that is critical for normal GI function. Disruption of GI motility frequently occurs in GI diseases or as side effects of therapeutics. Whole gut transit measurements, like carmine red leading‐edge transit, in mice form the cornerstone of in vivo preclinical GI motility studies.MethodWe have developed an easily achievable, labor‐saving method to measure whole gut transit time in mice. This approach uses inexpensive, commercially available materials to monitor pellet production over time via high definition cameras capturing time‐lapse video for offline analysis.Key ResultWe describe the assembly of our automated gut transit setup and validate this approach by comparing the results with loperamide to delay transit and conventional transit measurements. We demonstrate that compared to the control group, the loperamide group had slowed transit, evidenced by a decrease in total pellet production and prolonged whole gut transit time. The control group had an extended transit time compared with the results reported in the literature. Whole gut transit rates accelerated to times comparable to the literature by disrupting cages every 10‐15 min to imitate the conventional approach, suggesting that disruption affects the assay and supports the use of an automated approach.Conclusion & InferencesA novel automated, inexpensive, and easily assembled whole gut transit setup is labor‐saving and allows minimal disruption to animal behavior compared with the conventional approach.